The authors review a House Oversight Committee investigation report on AbbVie’s practices pertaining to adalimumab (Humira) to shed light on broader pharmaceutical market dynamics hindering a competitive market.
Micaela Laber, MPH, MBA
Advertisement
Articles by Micaela Laber, MPH, MBA
Advertisement
Latest Updated Articles
- Humira: The First $20 Billion Drug
Published: February 8th 2023 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
A "One-Two Punch" to Innovation? The Most Favored Nation Order and Broader US Drug Pricing Reform
2
Telemedicine Boosts Quality of Life, Inhaler Technique for Severe COPD
3
Bispecific Antibodies in Multiple Myeloma Are Moving From Clinical Trials to Community Practice
4
White House to Announce Second Drug Pricing Deal as AstraZeneca Joins TrumpRx
5
